DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Pirarubicin is an investigational drug.
There have been 21 clinical trials for Pirarubicin. The most recent clinical trial was a Phase 3 trial, which was initiated on June 1st 2019.
The most common disease conditions in clinical trials are Carcinoma, Carcinoma, Transitional Cell, and Breast Neoplasms. The leading clinical trial sponsors are Beijing Jishuitan Hospital, Peking University First Hospital, and Peking University People's Hospital.
There is one US patent protecting this investigational drug and sixteen international patents.
Recent Clinical Trials for Pirarubicin
|Adjuvant Chemotherapy for Triple Negative Breast Cancer Patients With Residual Disease After Neoadjuvant Chemotherapy||Chinese Academy of Medical Sciences||Phase 2|
|Combination Therapy of Anthracyclines for Children With Nephroblastoma||Shengjing Hospital||Phase 4|
|Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma||Tianjin Medical University Cancer Institute and Hospital||Phase 2|
Top disease conditions for Pirarubicin
Top clinical trial sponsors for Pirarubicin
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Pirarubicin||Start Trial||Heat shock protein 70 (hsp-70) receptor ligands||Duke University (Durham, NC)||Start Trial|
|Pirarubicin||Start Trial||Monomethylvaline compounds having phenylalanine side-chain modification at the C-terminus||Seattle Genetics, Inc. (Bothell, WA)||Start Trial|
|Pirarubicin||Start Trial||Bispecific antigen-binding constructs targeting HER2||Zymeworks Inc. (Vancouver, CA)||Start Trial|
|Pirarubicin||Start Trial||Use of inhibitors of Bruton's tyrosine kinase (Btk)||Pharmacyclics LLC (Sunnyvale, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|Pirarubicin||World Intellectual Property Organization (WIPO)||2015148714||2034-03-25||Start Trial|
|Pirarubicin||European Patent Office||1917020||2025-07-07||Start Trial|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|